Interestingly, a recent study demonstrated an additional vulnerability of IDH1/2 mutant gliomas with increased abundance of the oncometabolite D-2-HG, namely, sensitivity to histone deacetylases (HDACs) inhibitors [36]. This evidence concerns the gene IDH1 and glioma.